Thomson Reuters
Former drug company executive Martin Shkreli is surrounded by news cameras as he exits U.S. District Court following the second day of jury deliberations in his securities fraud trial in the Brooklyn borough of New York City
Shkreli, the notorious former pharma CEO, made headlines in September 2015 after he raised the price of Daraprim, a drug used to treat a parasitic infection, by 5,000%. The charges for this trial weren't related to the price hike; they were about events from earlier in his career while he managed hedge funds.
In court, his lawyer argued that his notoriety shouldn't influence the case.
"You may not like Martin Shkreli," Shkreli's lawyer Ben Brafman said in the case's opening statement. "And you may have reasons to hate Martin Shkreli, but that is not a basis on which to convict."
Prosecutors on the other hand, claimed that starting in 2009, Shkreli lost money in two of the hedge funds he ran, hid that from his investors, and instead paid them back with money he obtained from Retrophin.
Shkreli faced up to 20 years in jail.
This story is developing.